SG11202106534RA - Claudin18.2 binding moieties and uses thereof - Google Patents

Claudin18.2 binding moieties and uses thereof

Info

Publication number
SG11202106534RA
SG11202106534RA SG11202106534RA SG11202106534RA SG11202106534RA SG 11202106534R A SG11202106534R A SG 11202106534RA SG 11202106534R A SG11202106534R A SG 11202106534RA SG 11202106534R A SG11202106534R A SG 11202106534RA SG 11202106534R A SG11202106534R A SG 11202106534RA
Authority
SG
Singapore
Prior art keywords
binding moieties
moieties
binding
Prior art date
Application number
SG11202106534RA
Other languages
English (en)
Inventor
Liusong Yin
Tielin Zhou
Zhuo Fang
Yong Liu
Qiuchuan Zhuang
Bo Wu
Xiaohu Fan
Qingshan Zhang
Dan Zhao
Jie Mao
Original Assignee
Nanjing Genscript Biotech Co Ltd
Nanjing Legend Biotech Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nanjing Genscript Biotech Co Ltd, Nanjing Legend Biotech Co Ltd filed Critical Nanjing Genscript Biotech Co Ltd
Publication of SG11202106534RA publication Critical patent/SG11202106534RA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3046—Stomach, Intestines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
SG11202106534RA 2018-12-28 2019-12-27 Claudin18.2 binding moieties and uses thereof SG11202106534RA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2018125052 2018-12-28
CN2019095827 2019-07-12
PCT/CN2019/129017 WO2020135674A1 (fr) 2018-12-28 2019-12-27 Fractions de liaison de claudine 18.2 et leurs utilisations

Publications (1)

Publication Number Publication Date
SG11202106534RA true SG11202106534RA (en) 2021-07-29

Family

ID=71127698

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202106534RA SG11202106534RA (en) 2018-12-28 2019-12-27 Claudin18.2 binding moieties and uses thereof

Country Status (12)

Country Link
US (1) US20220073643A1 (fr)
EP (1) EP3902839A4 (fr)
JP (1) JP2022515487A (fr)
KR (1) KR20210110339A (fr)
CN (1) CN113227146B (fr)
AU (1) AU2019415848A1 (fr)
BR (1) BR112021012608A2 (fr)
CA (1) CA3125193A1 (fr)
IL (1) IL284393A (fr)
MX (1) MX2021007939A (fr)
SG (1) SG11202106534RA (fr)
WO (1) WO2020135674A1 (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113637082A (zh) * 2020-04-27 2021-11-12 启愈生物技术(上海)有限公司 一种靶向人claudin和人PDL1蛋白的双特异抗体及其应用
CN113929780A (zh) * 2020-07-13 2022-01-14 北京凯因科技股份有限公司 一种结合密蛋白的用于治疗癌症的人源化抗体
KR20230079397A (ko) * 2020-09-28 2023-06-07 엘피사이언스 (쑤저우) 바이오파마, 엘티디. 신규 항-클라우딘18 항체
CA3200974A1 (fr) 2020-11-08 2022-05-12 Seagen Inc. Polytherapie
CA3199212A1 (fr) * 2020-11-27 2022-06-02 Junji DONG Anticorps anti-cldn18.2 et son utilisation
CN114539402A (zh) * 2020-11-27 2022-05-27 南京北恒生物科技有限公司 靶向Claudin18.2的抗体及其用途
WO2022122709A1 (fr) 2020-12-07 2022-06-16 Sotio Biotech A.S. Conjugués anticorps-médicament à base d'anticorps cldn18.2 humanisés
MX2023007644A (es) 2020-12-23 2023-07-07 Sotio Biotech A S Conjugados anticuerpo-farmaco especificos para tumores con claudina 18.2.
CN113321730B (zh) * 2021-01-11 2023-10-10 上海莱馥医疗科技有限公司 Cldn18.2抗体及其应用
WO2022166940A1 (fr) * 2021-02-08 2022-08-11 Shandong Boan Biotechnology Co., Ltd. Anticorps bispécifiques cldn18.2/cd3 pour thérapie de tumeurs solides exprimant cldn18.2
CN115109154A (zh) * 2021-03-17 2022-09-27 三优生物医药(上海)有限公司 一种靶向cldn18.2的抗体或其抗原结合片段及其应用
WO2024096577A1 (fr) * 2022-11-01 2024-05-10 앱티스 주식회사 Composé comprenant une unité de liaison à fc, et conjugué préparé à l'aide de celui-ci
CN116284224B (zh) * 2023-05-12 2023-07-25 中国农业大学 一种结合Claudin 18.2的环肽及其应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1790664A1 (fr) * 2005-11-24 2007-05-30 Ganymed Pharmaceuticals AG Anticorps monoclonaux contre claudin-18 pour le traitement du cancer
EP1997832A1 (fr) * 2007-05-29 2008-12-03 Ganymed Pharmaceuticals AG Anticorps monoclonaux contre la claudine-18 pour le traitement contre le cancer
WO2013174404A1 (fr) * 2012-05-23 2013-11-28 Ganymed Pharmaceuticals Ag Polythérapie impliquant des anticorps dirigés contre la claudine 18,2 pour le traitement du cancer
WO2013174403A1 (fr) * 2012-05-23 2013-11-28 Ganymed Pharmaceuticals Ag Polythérapie impliquant des anticorps dirigés contre la claudine 18,2 pour le traitement du cancer
WO2014127785A1 (fr) * 2013-02-20 2014-08-28 Ganymed Pharmaceuticals Ag Polythérapie impliquant des anticorps dirigés contre la claudine 18,2 pour le traitement du cancer
CN105315375B (zh) * 2014-07-17 2021-04-23 恺兴生命科技(上海)有限公司 靶向cld18a2的t淋巴细胞及其制备方法和应用
WO2016165762A1 (fr) * 2015-04-15 2016-10-20 Ganymed Pharmaceuticals Ag Conjugués de médicaments comprenant des anticorps contre la claudine 18.2
WO2016180468A1 (fr) * 2015-05-11 2016-11-17 Biontech Cell & Gene Therapies Gmbh Épitopes des cellules t et immunorécepteurs spécifiques de claudine-18.2
CN109790222B (zh) * 2016-07-08 2022-03-15 克莱格医学有限公司 抗密蛋白18a2的抗体及其应用
US11059887B2 (en) * 2018-05-18 2021-07-13 Lanova Medicines Limited Company Anti-claudin 18.2 antibodies and uses thereof
WO2020160560A2 (fr) * 2019-02-01 2020-08-06 Novarock Biotherapeutics, Ltd. Anticorps anti-claudine 18 et leurs méthodes d'utilisation
MX2022002111A (es) * 2019-08-20 2022-03-17 Suzhou Transcenta Therapeutics Co Ltd Novedosos anticuerpos anti-cldn18.2.

Also Published As

Publication number Publication date
BR112021012608A2 (pt) 2021-09-08
WO2020135674A1 (fr) 2020-07-02
KR20210110339A (ko) 2021-09-07
CN113227146B (zh) 2024-03-01
US20220073643A1 (en) 2022-03-10
CA3125193A1 (fr) 2020-07-02
EP3902839A4 (fr) 2022-12-14
EP3902839A1 (fr) 2021-11-03
AU2019415848A1 (en) 2021-08-19
AU2019415848A8 (en) 2021-09-02
JP2022515487A (ja) 2022-02-18
CN113227146A (zh) 2021-08-06
IL284393A (en) 2021-08-31
MX2021007939A (es) 2021-10-22

Similar Documents

Publication Publication Date Title
IL284393A (en) The claudin18.2 binding groups and their uses
IL276830A (en) Anti-claudin 18.2 antibodies and uses thereof
SG11202007074PA (en) Anti-claudin 18.2 antibodies and uses thereof
IL278888A (en) PSMA binding agents and their uses
SG11202100931QA (en) Muscle-targeting complexes and uses thereof
IL277398A (en) PD-L1 binding epimers and related uses thereof
ZA202103061B (en) Anti-cldn18.2 antibody and uses thereof
IL279133A (en) Binder-drug conjugates activated in the microenvironment and their related uses
IL272064A (en) Binding proteins 1
ZA202106880B (en) Anti-claudin 18.2 antibody and application thereof
GB201900437D0 (en) Axial3d big book 2
IL278877A (en) Amino-pyrazinecarboxamide compounds, conjugates and their uses
SG11202011685QA (en) 2,3-dihydro-1h-pyrrolizine-7-formamide derivative and application thereof
EP4081551A4 (fr) Fractions de liaison à claudin18.2 et leurs utilisations
IL272055A (en) 8,1-naphthyridinone compounds and their uses
SG11202101517PA (en) Isoquinoline-steroid conjugates and uses thereof
IL284765A (en) 8,1-naphthyridinone compounds and their uses
SG11202010596PA (en) Soluble complement receptor type 1 variants and uses thereof
GB202015822D0 (en) 66.123.142648/01
Darvas You Can Still Market It In the Market
Chetiapatar Bihu Geetok Samajik Chitro
Quin Tripticks
Sharma Sahitya And Sankskriti
GB201819687D0 (en) Mrbr.5
Malik Nal Birina Khagori